litlas
Log inCreate account

Philippe Rousselot

Active 1990–2025

127
Papers
26,995
Citations
76
h-index
122
i10-index

Citations

Citations per year for Philippe Rousselot1979: 8 citations1991: 1 citations1992: 5 citations1993: 3 citations1994: 3 citations1995: 5 citations1996: 9 citations1997: 12 citations1998: 12 citations1999: 16 citations2000: 14 citations2001: 23 citations2002: 30 citations2003: 70 citations2004: 95 citations2005: 81 citations2006: 101 citations2007: 186 citations2008: 203 citations2009: 190 citations2010: 188 citations2011: 173 citations2012: 181 citations2013: 177 citations2014: 191 citations2015: 219 citations2016: 233 citations2017: 216 citations2018: 215 citations2019: 774 citations2020: 796 citations2021: 665 citations2022: 464 citations2023: 307 citations2024: 695 citations2025: 316 citations2026: 2 citations1980–1990: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,093 citing papers, 25.7% of this breakdownFrance: 636 citing papers, 7.8% of this breakdownGermany: 612 citing papers, 7.5% of this breakdownItaly: 581 citing papers, 7.1% of this breakdownUnited Kingdom: 539 citing papers, 6.6% of this breakdownChina: 459 citing papers, 5.6% of this breakdownCanada: 241 citing papers, 3% of this breakdownAustralia: 240 citing papers, 3% of this breakdownSpain: 219 citing papers, 2.7% of this breakdownSwitzerland: 217 citing papers, 2.7% of this breakdownNetherlands: 201 citing papers, 2.5% of this breakdownJapan: 190 citing papers, 2.3% of this breakdown
0%25.7%Other 23.5%

Institutions

Fields

  • Medicine75.8%
  • Biochemistry, Genetics and Molecular Biology16.6%
  • Immunology and Microbiology3.8%
  • Computer Science0.6%
  • Chemistry0.5%
  • Materials Science0.4%
  • Other2.3%

Topics

  • Chronic Myeloid Leukemia Treatments14%
  • Acute Myeloid Leukemia Research9%
  • Chronic Lymphocytic Leukemia Research7.4%
  • Acute Lymphoblastic Leukemia research6.1%
  • Eosinophilic Disorders and Syndromes5.8%
  • CAR-T cell therapy research2.4%
  • Other55.3%

Coauthors

All papers

Open in search
  1. Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study

    Authors: Sylvie Castaigné, Cécile Pautas, Christine Terré, Emmanuel Raffoux, Dominique Bordessoule, Jean Bastié, Ollivier Legrand, Xavier Thomas, Pascal Turlure, Oumédaly Reman, Thierry de Revel, Lauris Gastaud, Noémie de Gunzburg, Nathalie Contentin, Estelle Henry, Jean‐Pierre Marolleau, Ahmad Aljijakli, Philippe Rousselot, Pierre Fenaux, Claude Preudhomme, Sylvie Chevret, Hervé Dombret - The Lancet 2012 cited by 995

  2. Five-Year Follow-up of Patients Receiving Imatinib for Chronic Myeloid Leukemia

    Authors: Brian Druker, François Guilhot, Stephen G. O’Brien, Insa Gathmann, Hagop M. Kantarjian, Norbert Gattermann, Michael W. Deininger, Richard T. Silver, John M. Goldman, Richard M. Stone, Francisco Cervantes, Andreas Hochhaus, Bayard L. Powell, Janice Gabrilove, Philippe Rousselot, Josy Reiffers, Jan J. Cornelissen, Timothy P. Hughes, Hermine Agis, Thomas Fischer, Gregor Verhoef, John D. Shepherd, Giuseppe Saglio, Aloïs Gratwohl, Johan Lanng Nielsen, Jerald P. Radich, Bengt Simonsson, Kerry Taylor, Michele Baccarani, Charlene So, Laurie Letvak, Richard A. Larson - New England Journal of Medicine 2006 cited by 3,481

  3. Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial

    Authors: François‐Xavier Mahon, Delphine Réa, Joëlle Guilhot, François Guilhot, Françoise Huguet, Franck E. Nicolini, Laurence Legros, Aude Charbonnier, Agnès Guerci, Bruno Varet, Gabriel Étienne, Josy Reiffers, Philippe Rousselot - The Lancet Oncology 2010 cited by 1,538

  4. Ponatinib dose-ranging study in chronic-phase chronic myeloid leukemia: a randomized, open-label phase 2 clinical trial

    Authors: Jörge E. Cortes, Jane F. Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles A. Schiffer, James McCloskey, Andreas Hochhaus, Philippe Rousselot, Gianantonio Rosti, Hugues de Lavallade, Anna Turkina, Christine Rojas, Christopher Arthur, Lori J. Maness, Moshe Talpaz, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael Deininger - Blood 2021 cited by 193

  5. Imatinib Compared with Interferon and Low-Dose Cytarabine for Newly Diagnosed Chronic-Phase Chronic Myeloid Leukemia

    Authors: Stephen G. O’Brien, François Guilhot, Richard A. Larson, Insa Gathmann, Michele Baccarani, Francisco Cervantes, Jan J. Cornelissen, Thomas Fischer, Andreas Hochhaus, Timothy P. Hughes, Klaus Lechner, Johan Lanng Nielsen, Philippe Rousselot, Josy Reiffers, Giuseppe Saglio, John D. Shepherd, Bengt Simonsson, Aloïs Gratwohl, John M. Goldman, Hagop M. Kantarjian, Kerry Taylor, Gregor Verhoef, Ann E. Bolton, Renaud Capdeville, Brian Druker - New England Journal of Medicine 2003 cited by 3,565

  6. Discontinuation of tyrosine kinase inhibitor therapy in chronic myeloid leukaemia (EURO-SKI): a prespecified interim analysis of a prospective, multicentre, non-randomised, trial

    Authors: Susanne Saußele, Johan Richter, Joëlle Guilhot, Franz Gruber, Henrik Hjorth-Hansen, António Almeida, Jeroen J. W. M. Janssen, Jiřı́ Mayer, Perttu Koskenvesa, Panayiotis Panayiotidis, Ulla Olsson‐Strömberg, Joaquín Martínez‐López, Philippe Rousselot, Hanne Vestergaard, Hans Ehrencrona, Veli Kairisto, Kateřina Machová Poláková, Martin C. Müller, Satu Mustjoki, Marc Berger, Alice Fabarius, Wolf‐Karsten Hofmann, Andreas Hochhaus, Markus Pfirrmann, François‐Xavier Mahon, Gert J. Ossenkoppele, Maria Pagoni, Stina Söderlund, Martine Escoffre‐Barbe, Gabriel Étienne, Jolanta Dengler, Françoise Huguet, Nikolas von Bubnoff, Hana Klamová, Edgar Faber, François Guilhot, Kourosh Lotfi, Delphine Réa, Tim H. Brümmendorf, G.E. de Greef, Leif Stenke, Franck E. Nicolini, Laurence Legros, Andreas Burchert, J Voglová, Aude Charbonnier, Emmanuel Gyan, Volker Kunzmann, Peter E. Westerweel - The Lancet Oncology 2018 cited by 611

  7. Bosutinib versus imatinib for newly diagnosed chronic phase chronic myeloid leukemia: final results from the BFORE trial

    Authors: Tim H. Brümmendorf, Jörge E. Cortes, Dragana Milojković, Carlo Gambacorti‐Passerini, Richard E. Clark, Philipp le Coutre, Valentín García‐Gutiérrez, Charles Chuah, Vamsi Kota, Jeffrey H. Lipton, Philippe Rousselot, Michael J. Mauro, Andreas Hochhaus, Rafael Hurtado Monroy, Eric Leip, Simon Purcell, Anne Yver, Andrea Viqueira, Michael W. Deininger, BFORE study investigators - Leukemia 2022 cited by 141

  8. Ponatinib vs Imatinib in Frontline Philadelphia Chromosome–Positive Acute Lymphoblastic Leukemia

    Authors: Elias Jabbour, Hagop M. Kantarjian, Ibrahim Aldoss, Pau Montesinos, Jessica Leonard, David Gómez‐Almaguer, Maria R. Baer, Carlo Gambacorti‐Passerini, James McCloskey, Yosuke Minami, Cristina Papayannidis, Vanderson Rocha, Philippe Rousselot, Pankit Vachhani, Eunice S. Wang, Bingxia Wang, Meliessa Hennessy, Alexander Vorog, Niti Patel, Tammie C. Yeh, Josep‐María Ribera - JAMA 2024 cited by 114

  9. European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Authors: Michele Baccarani, Michael Deininger, Gianantonio Rosti, Andreas Hochhaus, Simona Soverini, Jane F. Apperley, Francisco Cervantes, Richard E. Clark, Jörge E. Cortes, François Guilhot, Henrik Hjorth‐Hansen, Timothy P. Hughes, Hagop M. Kantarjian, Dong‐Wook Kim, Richard A. Larson, Jeffrey H. Lipton, François-Xavier Mahon, Giovanni Martinelli, Jiřı́ Mayer, Martin Müller, Dietger Niederwieser, Fabrizio Pane, Jerald P. Radich, Philippe Rousselot, Giuseppe Saglio, Susanne Saußele, Charles A. Schiffer, Richard T. Silver, Bengt Simonsson, Juan-Luis Steegmann, John M. Goldman, Rüdiger Hehlmann - Blood 2013 cited by 1,989

  10. Dasatinib and low-intensity chemotherapy in elderly patients with Philadelphia chromosome–positive ALL

    Authors: Philippe Rousselot, marie Magdelaine Coude, Nicola Gökbuget, Carlo Gambacorti‐Passerini, Sandrine Hayette, Jean‐Michel Cayuela, Françoise Huguet, Thibaut Leguay, Patrice Chevallier, Célia Salanoubat, Caroline Bonmati, Magda Alexis, Mathilde Hunault, Sylvie Glaisner, Philippe Agapé, Christian Berthou, Éric Jourdan, José Fernandes, Laurent Sutton, Anne Banos, Oumédaly Reman, Bruno Lioure, Xavier Thomas, Norbert Ifrah, Mårina Lafage‐Pochitaloff, Anne Bornand, Laure Morisset, Valérie Robin, Heike Pfeifer, André Delannoy, Josep‐María Ribera, Renato Bassan, Marc Delord, Dieter Hoelzer, Hervé Dombret, Oliver G. Ottmann - Blood 2016 cited by 326

  11. Long-Term Follow-Up of the French Stop Imatinib (STIM1) Study in Patients With Chronic Myeloid Leukemia

    Authors: Gabriel Étienne, Joëlle Guilhot, Delphine Réa, Françoise Rigal‐Huguet, Franck E. Nicolini, Aude Charbonnier, Agnès Guerci‐Bresler, Laurence Legros, Bruno Varet, Martine Gardembas, Viviane Dubruille, Michel Tulliez, Marie‐Pierre Noël, Jean‐Christophe Ianotto, Bruno Villemagne, Martin Carré, François Guilhot, Philippe Rousselot, François‐Xavier Mahon - Journal of Clinical Oncology 2016 cited by 494

  12. Randomized study of reduced-intensity chemotherapy combined with imatinib in adults with Ph-positive acute lymphoblastic leukemia

    Authors: Yves Chalandon, Xavier Thomas, Sandrine Hayette, Jean‐Michel Cayuela, Claire Abbal, Françoise Huguet, Emmanuel Raffoux, Thibaut Leguay, Philippe Rousselot, Stéphane Leprêtre, Martine Escoffre‐Barbe, Sébastien Maury, Céline Berthon, Emmanuelle Tavernier, Jean‐François Lambert, Mårina Lafage‐Pochitaloff, Véronique Lhéritier, Sylvie Chevret, Norbert Ifrah, Hervé Dombret - Blood 2015 cited by 374

  13. Moxetumomab pasudotox in relapsed/refractory hairy cell leukemia

    Authors: Robert J. Kreitman, Claire Dearden, Pier Luigi Zinzani, Julio Delgado, Lionel Karlin, Tadeusz Robak, Douglas E. Gladstone, Philipp le Coutre, Sascha Dietrich, Mirjana Gotić, Loree Larratt, Fritz Offner, Gary J. Schiller, Ronan Swords, Larry Bacon, Monica Bocchia, Krimo Bouabdallah, Dimitri Breems, Agostino Cortelezzi, Shira Dinner, Michael Doubek, Bjørn Tore Gjertsen, Marco Gobbi, Andrzej Hellmann, Stéphane Leprêtre, Frédéric Maloisel, Farhad Ravandi, Philippe Rousselot, Mathias Rummel, Tanya Siddiqi, Tamar Tadmor, Xavier Troussard, Cecilia Arana Yi, Giuseppe Saglio, Gail J. Roboz, Kemal Balic, Nathan Standifer, Peng He, Shannon Marshall, Wyndham H. Wilson, Ira Pastan, Nai-Shun Yao, Francis J. Giles - Leukemia 2018 cited by 247

  14. Quizartinib, an FLT3 inhibitor, as monotherapy in patients with relapsed or refractory acute myeloid leukaemia: an open-label, multicentre, single-arm, phase 2 trial

    Authors: Jörge E. Cortes, Alexander E. Perl, Hartmut Döhner, Hagop M. Kantarjian, Giovanni Martinelli, Tibor Kovacsovics, Philippe Rousselot, Björn Steffen, Hervé Dombret, Elihu H. Estey, Stephen A. Strickland, Jessica K. Altman, Claudia D. Baldus, Alan K. Burnett, Alwin Krämer, Nigel H. Russell, Neil P. Shah, Catherine C. Smith, Eunice S. Wang, Norbert Ifrah, Guy Gammon, Denise Trone, Deborah Lazzaretto, Mark J. Levis - The Lancet Oncology 2018 cited by 264

  15. Dasatinib induces lung vascular toxicity and predisposes to pulmonary hypertension

    Authors: Christophe Guignabert, Carole Phan, Andrei Seferian, Alice Huertas, Ly Tu, Raphaël Thuillet, C.H. Sattler, Morane Le Hiress, Yuichi Tamura, Etienne‐Marie Jutant, Marie‐Camille Chaumais, Stéphane Bouchet, Benjamin Manéglier, Mathiéu Molimard, Philippe Rousselot, Olivier Sitbon, Gérald Simonneau, David Montani, Marc Humbert - Journal of Clinical Investigation 2016 cited by 273

  16. Intensified Therapy of Acute Lymphoblastic Leukemia in Adults: Report of the Randomized GRAALL-2005 Clinical Trial

    Authors: Françoise Huguet, Sylvie Chevret, Thibaut Leguay, Xavier Thomas, Nicolas Boissel, Martine Escoffre‐Barbe, Patrice Chevallier, Mathilde Hunault, Norbert Vey, Caroline Bonmati, Stéphane Leprêtre, Jean‐Pierre Marolleau, Thomas Pabst, Philippe Rousselot, Agnès Buzyn, Jean‐Yves Cahn, Véronique Lhéritier, Marie C. Béné, Vahid Asnafi, Éric Delabesse, Elizabeth Macintyre, Yves Chalandon, Norbert Ifrah, Hervé Dombret - Journal of Clinical Oncology 2018 cited by 151

  17. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel

    Authors: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 cited by 76

  18. Management of ALL in adults: 2024 ELN recommendations from a European expert panel

    Authors: Nicola Gökbuget, Nicolas Boissel, Sabina Chiaretti, Hervé Dombret, Michael Doubek, Adele K. Fielding, Robin Foà, Sebastian Giebel, Dieter Hoelzer, Mathilde Hunault, David I. Marks, Giovanni Martinelli, Oliver G. Ottmann, Anita W. Rijneveld, Philippe Rousselot, Josep‐María Ribera, Renato Bassan - Blood 2024 cited by 109

  19. BCR-ABL1 Compound Mutations Combining Key Kinase Domain Positions Confer Clinical Resistance to Ponatinib in Ph Chromosome-Positive Leukemia

    Authors: Matthew S. Zabriskie, Christopher A. Eide, Srinivas K. Tantravahi, Nadeem A. Vellore, Johanna Estrada, Franck E. Nicolini, H. Jean Khoury, Richard A. Larson, Marina Konopleva, Jörge E. Cortes, Hagop M. Kantarjian, Elias Jabbour, Steven M. Kornblau, Jeffrey H. Lipton, Delphine Réa, Leif Stenke, Gisela Barbany, Thoralf Lange, Juan Carlos Hernández‐Boluda, Gert J. Ossenkoppele, Richard D. Press, Charles Chuah, Stuart L. Goldberg, Meir Wetzler, François-Xavier Mahon, Gabriel Étienne, Michele Baccarani, Simona Soverini, Gianantonio Rosti, Philippe Rousselot, Ran Friedman, Marie Deininger, Kimberly R. Reynolds, William L. Heaton, Anna M. Eiring, Anthony D. Pomicter, Jamshid S. Khorashad, Todd W. Kelley, Riccardo Baron, Brian Druker, Michael W. Deininger, Thomas O’Hare - Cancer Cell 2014 cited by 366

  20. Novel precision medicine approaches and treatment strategies in hematological malignancies

    Authors: Richard Rosenquist, Elsa Bernard, Tom Erkers, David W. Scott, Raphaël Itzykson, Philippe Rousselot, Jean Soulier, Martin Hutchings, Päivi Östling, Lucia Cavelier, Thoas Fioretos, Karin E. Smedby - Journal of Internal Medicine 2023 cited by 45

  21. Loss of Major Molecular Response As a Trigger for Restarting Tyrosine Kinase Inhibitor Therapy in Patients With Chronic-Phase Chronic Myelogenous Leukemia Who Have Stopped Imatinib After Durable Undetectable Disease

    Authors: Philippe Rousselot, Aude Charbonnier, Pascale Cony‐Makhoul, Philippe Agapé, Franck E. Nicolini, Bruno Varet, Martine Gardembas, Gabriel Étienne, Delphine Réa, Lydia Roy, Martine Escoffre‐Barbe, Agnès Guerci‐Bresler, Michel Tulliez, Stéphane Prost, Marc Spentchian, Jean Michel Cayuela, Josy Reiffers, Jean‐Claude Chomel, Ali G. Turhan, Joëlle Guilhot, François Guilhot, François‐Xavier Mahon - Journal of Clinical Oncology 2013 cited by 409

  22. Discontinuation of dasatinib or nilotinib in chronic myeloid leukemia: interim analysis of the STOP 2G-TKI study

    Authors: Delphine Réa, Franck E. Nicolini, Michel Tulliez, François Guilhot, Joëlle Guilhot, Agnès Guerci‐Bresler, Martine Gardembas, Valérie Coiteux, Gaëlle Guillerm, Laurence Legros, Gabriel Étienne, Jean‐Michel Pignon, Bruno Villemagne, Martine Escoffre‐Barbe, Jean‐Christophe Ianotto, Aude Charbonnier, Hyacinthe Johnson‐Ansah, Marie‐Pierre Noël, Philippe Rousselot, François‐Xavier Mahon, for the France Intergroupe des Leucémies Myéloïdes Chroniques - Blood 2016 cited by 317

  23. Efficacy of tyrosine kinase inhibitors in Ph-like acute lymphoblastic leukemia harboring ABL-class rearrangements

    Authors: Ilaria Tanasi, Ibrahima Ba, Nicolas Sirvent, Thorsten Braun, Wendy Cuccuini, Paola Ballerini, Nicolas Duployez, Aline Schmidt, Jérôme Tamburini, Sébastien Maury, Éric Doré, Chantal Himberlin, Cédric Duclos, Patrice Chevallier, Philippe Rousselot, Massimiliano Bonifacio, Hélène Cavé, André Baruchel, Hervé Dombret, Jean Soulier, Judith Landman‐Parker, Nicolas Boissel, Emmanuelle Clappier - Blood 2019 cited by 133

  24. Ponatinib after failure of second‐generation tyrosine kinase inhibitor in resistant chronic‐phase chronic myeloid leukemia

    Authors: Hagop M. Kantarjian, Elias Jabbour, Michael W. Deininger, Elisabetta Abruzzese, Jane F. Apperley, Jörge E. Cortes, Charles Chuah, Daniel J. DeAngelo, John F. DiPersio, Andreas Hochhaus, Jeffrey H. Lipton, Franck E. Nicolini, Javier Pinilla‐Ibarz, Delphine Réa, Gianantonio Rosti, Philippe Rousselot, Neil P. Shah, Moshe Talpaz, Shouryadeep Srivastava, Xiaowei Ren, Michael J. Mauro - American Journal of Hematology 2022 cited by 45